Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kinetically guided plasmafiltration with Caelyx in platinum-resistant ovarian carcinoma
2016-000971-26Phase 4Completed
- Sponsor
- Charles University
- Start
- Apr 2016
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pegylated liposomal doxorubicin in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Charles University. Primary endpoint: Progression of disease. Started Apr 2016; status: completed.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2016-000971-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000971-26.